Patient centred health technology assessment: a perspective on engagement in health technology assessment by three patient organisations and a health technology assessment body

20 October 2022 - Patient engagement in health technology assessment has become increasingly important over the past 20 years.  ...

Read more →

ICER publishes final evidence report and policy recommendations on treatments for obesity management

20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...

Read more →

ICER evaluates drug price increases in California

20 October 2022 - Unsupported Price Increase” final report based on drugs identified through SB-17, the California drug price transparency law. ...

Read more →

Can state prescription drug affordability boards address high cost drug prices?

11 October 2022 - State law makers, like their federal counterparts, are focused on addressing the high and growing cost of ...

Read more →

ICER releases draft evidence report on treatments for multiple sclerosis

17 October 2022 - Public comment period now open until 11 November 2022; requests to make oral comment during public ...

Read more →

New generation of weight loss medications offer promise — but at a price

11 October 2022 - Excitement is building about a new generation of drugs that tout the ability to help adults ...

Read more →

ICER releases draft evidence report on treatment for vasomotor symptoms associated with menopause

11 October 2022 - Registration now open for October 19 “Early Insights” webinar. ...

Read more →

ICER to assess treatments for non-alcoholic steatohepatitis

5 October 2022 - Report will be subject of Midwest CEPAC meeting in April 2023; Draft Scoping Document open to ...

Read more →

Newly approved ALS drug Relyvrio to face its next challenge: pricing and reimbursement

4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which ...

Read more →

ICER releases draft evidence report on gene therapies for haemophilia A and B

13 September 2022 - Registration now open for 20 September “Early Insights” webinar. ...

Read more →

ICER publishes final evidence report and policy recommendations on treatments for amyotrophic lateral sclerosis

13 September 2022 - Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral ...

Read more →

ICER publishes evidence report on treatments for obesity management

31 August 2022 - Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide ...

Read more →

ICER publishes evidence report on treatments for amyotrophic lateral sclerosis

4 August 2022 - Given current data, AMX0035 is comparable or better to standard of care; AMX0035 would achieve common thresholds ...

Read more →

ICER releases draft evidence report on treatments for obesity management

13 July 2022 - Registration now open for 26 July “Early Insights” webinar. ...

Read more →

ICER launches initiative to evaluate and advance health technology assessment methods that support health equity

11 July 2022 - Funding from Commonwealth Fund supports a broad based initiative exploring potential changes in all health technology assessment ...

Read more →